Psych CASC / OSCE · Psychopharmacology — atypical and multimodal antidepressants
Choosing bupropion after SSRI sexual dysfunction (CASC)
CASC-style station: explain NaSSA vs NDRI trade-offs, accurate seizure risk counselling, sexual side-effect management, smoking opportunity, and avoid casual combination starts.
On this page & tools
Target exams
Station instructions (candidate)
You have 7 minutes. Explore goals: mood recovery, sexual function, smoking, weight concerns. Explain that sertraline-related sexual dysfunction is common and treatable by strategy, not shame. Offer a collaborative plan that may include switching to or adding bupropion after screening for seizure risk factors, with a clear oral dose plan and early review. Contrast honestly with mirtazapine (helpful for sleep/appetite; sedation and weight gain trade-offs). Do not claim zero seizure risk. Do not start venlafaxine+mirtazapine tonight as casual "rocket fuel." Do not dismiss online fears.[1][3][4][6][7]
Marking domains
Rapport and agenda setting; accurate sexual side-effect validation; bipolar screen mentioned; bupropion mechanism in plain language; seizure risk explained without terror or denial; smoking dual benefit opportunity; mirtazapine contrast; dose and follow-up plan; shared decision and right to decline; safety netting for activation/suicidality.[1][2][4][5][8]
Model communication map
- Open: thank them; name priorities (mood, sex, smoking, not gaining weight).[8]
- Validate sexual SE: many people on serotonergic antidepressants get delayed orgasm or lower desire — it is a drug effect we take seriously, not a personal failing.[3]
- Options in plain language: keep/adjust sertraline; switch to bupropion; or add bupropion if mood partly better — trials support bupropion after SSRI incomplete response as switch or augment.[1][2]
- What bupropion is: works more on noradrenaline and dopamine systems than serotonin reuptake; often kinder to sexual function in comparative data.[3]
- Seizure honesty: seizures are uncommon at usual modern doses but risk rises with certain histories (eating disorders, alcohol withdrawal, prior seizures, very high doses) — we screen, we do not pretend risk is zero.[4]
- Smoking: same medicine class has controlled-trial evidence for helping people stop smoking with support; we can pair with behavioural help or nicotine replacement if wanted.[5]
- Mirtazapine contrast: excellent when sleep and appetite are the main problems because of different receptor effects, but often increases sleepiness and weight — not your preferred trade-off today.[6]
- Plan if agreeing: example bupropion XL 150 mg daily then 300 mg if tolerated; early phone/clinic review; crisis contacts; do not stack random extra antidepressants tonight (combinations are for selected later steps, not automatic).[1][7][8]
- If declining medicine change: honour choice; sex-focused strategies and therapy still available; door open.[8]
- Close: written plan; what to do if agitation or suicidal thoughts increase after change.[8]
Risk and safety notes for examiner
Candidate should not invent MAOI combinations, minimise eating-disorder seizure risk, promise bupropion never causes seizures, or start dual SNRI+mirtazapine without TRD framing.[4][7]
References
- [1]Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression N Engl J Med, 2006.PMID 16554525
- [2]Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression N Engl J Med, 2006.PMID 16554526
- [3]Thase ME, Clayton AH, Haight BR, et al. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability J Clin Psychopharmacol, 2006.PMID 16974189
- [4]Davidson J Seizures and bupropion: a review J Clin Psychiatry, 1989.PMID 2500425
- [5]Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation N Engl J Med, 1999.PMID 10053177
- [6]de Boer T The pharmacologic profile of mirtazapine J Clin Psychiatry, 1996.PMID 8636062
- [7]Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study Am J Psychiatry, 2011.PMID 21536692
- [8]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391